nodes	percent_of_prediction	percent_of_DWPC	metapath
Eprosartan—ABCC2—Paclitaxel—kidney cancer	0.107	0.165	CbGbCtD
Eprosartan—ABCC2—Sorafenib—kidney cancer	0.0948	0.147	CbGbCtD
Eprosartan—ABCC2—Vinblastine—kidney cancer	0.0936	0.145	CbGbCtD
Eprosartan—ABCC2—Vincristine—kidney cancer	0.092	0.142	CbGbCtD
Eprosartan—ABCC2—Sunitinib—kidney cancer	0.0768	0.119	CbGbCtD
Eprosartan—ABCC2—Doxorubicin—kidney cancer	0.0575	0.089	CbGbCtD
Eprosartan—CYP2C9—Capecitabine—kidney cancer	0.0572	0.0886	CbGbCtD
Eprosartan—CYP2C9—Paclitaxel—kidney cancer	0.0358	0.0555	CbGbCtD
Eprosartan—CYP2C9—Sorafenib—kidney cancer	0.0318	0.0493	CbGbCtD
Eprosartan—AGTR1—nephron—kidney cancer	0.0163	0.343	CbGeAlD
Eprosartan—CYP2C9—urine—kidney cancer	0.00629	0.132	CbGeAlD
Eprosartan—AGTR1—nephron tubule—kidney cancer	0.00351	0.074	CbGeAlD
Eprosartan—AGTR1—renal system—kidney cancer	0.00319	0.0673	CbGeAlD
Eprosartan—AGTR1—kidney—kidney cancer	0.00309	0.065	CbGeAlD
Eprosartan—AGTR1—cortex of kidney—kidney cancer	0.00301	0.0633	CbGeAlD
Eprosartan—AGTR1—cardiac atrium—kidney cancer	0.00286	0.0602	CbGeAlD
Eprosartan—ABCC2—nephron tubule—kidney cancer	0.00254	0.0535	CbGeAlD
Eprosartan—ABCC2—renal system—kidney cancer	0.00231	0.0486	CbGeAlD
Eprosartan—ABCC2—kidney—kidney cancer	0.00223	0.047	CbGeAlD
Eprosartan—ABCC2—cortex of kidney—kidney cancer	0.00217	0.0458	CbGeAlD
Eprosartan—AGTR1—Allograft Rejection—HARS—kidney cancer	0.000771	0.0639	CbGpPWpGaD
Eprosartan—ABCC2—Codeine and Morphine Metabolism—ABCB1—kidney cancer	0.000635	0.0526	CbGpPWpGaD
Eprosartan—ABCC2—Irinotecan Pathway—BCHE—kidney cancer	0.000539	0.0446	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—LRRK2—kidney cancer	0.000443	0.0367	CbGpPWpGaD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—GRB7—kidney cancer	0.000422	0.035	CbGpPWpGaD
Eprosartan—AGTR1—Arf6 trafficking events—CTNNA1—kidney cancer	0.000374	0.031	CbGpPWpGaD
Eprosartan—ABCC2—Drug Induction of Bile Acid Pathway—ABCB1—kidney cancer	0.000347	0.0288	CbGpPWpGaD
Eprosartan—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—kidney cancer	0.000328	0.0272	CbGpPWpGaD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PAK1—kidney cancer	0.000295	0.0245	CbGpPWpGaD
Eprosartan—ABCC2—Irinotecan Pathway—APC—kidney cancer	0.000293	0.0242	CbGpPWpGaD
Eprosartan—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—kidney cancer	0.000257	0.0213	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—IL13—kidney cancer	0.000253	0.0209	CbGpPWpGaD
Eprosartan—AGTR1—Arf6 signaling events—MET—kidney cancer	0.000239	0.0198	CbGpPWpGaD
Eprosartan—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—kidney cancer	0.000234	0.0193	CbGpPWpGaD
Eprosartan—Dermatitis—Everolimus—kidney cancer	0.000216	0.000734	CcSEcCtD
Eprosartan—Headache—Vinblastine—kidney cancer	0.000216	0.000733	CcSEcCtD
Eprosartan—Angioedema—Paclitaxel—kidney cancer	0.000215	0.000732	CcSEcCtD
Eprosartan—Purpura—Doxorubicin—kidney cancer	0.000215	0.00073	CcSEcCtD
Eprosartan—Headache—Everolimus—kidney cancer	0.000215	0.00073	CcSEcCtD
Eprosartan—Hypotension—Gemcitabine—kidney cancer	0.000215	0.00073	CcSEcCtD
Eprosartan—Body temperature increased—Dactinomycin—kidney cancer	0.000214	0.000729	CcSEcCtD
Eprosartan—Abdominal pain—Dactinomycin—kidney cancer	0.000214	0.000729	CcSEcCtD
Eprosartan—Visual impairment—Capecitabine—kidney cancer	0.000214	0.000728	CcSEcCtD
Eprosartan—Asthenia—Sorafenib—kidney cancer	0.000214	0.000726	CcSEcCtD
Eprosartan—Malaise—Paclitaxel—kidney cancer	0.000213	0.000723	CcSEcCtD
Eprosartan—Cardiac failure—Doxorubicin—kidney cancer	0.000212	0.000721	CcSEcCtD
Eprosartan—Vertigo—Paclitaxel—kidney cancer	0.000212	0.00072	CcSEcCtD
Eprosartan—Syncope—Paclitaxel—kidney cancer	0.000211	0.000719	CcSEcCtD
Eprosartan—Hypersensitivity—Sunitinib—kidney cancer	0.000211	0.000717	CcSEcCtD
Eprosartan—Decreased appetite—Vincristine—kidney cancer	0.000211	0.000716	CcSEcCtD
Eprosartan—Pruritus—Sorafenib—kidney cancer	0.000211	0.000716	CcSEcCtD
Eprosartan—Vomiting—Erlotinib—kidney cancer	0.00021	0.000715	CcSEcCtD
Eprosartan—ABCC2—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	0.000209	0.0174	CbGpPWpGaD
Eprosartan—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000209	0.000712	CcSEcCtD
Eprosartan—Fatigue—Vincristine—kidney cancer	0.000209	0.00071	CcSEcCtD
Eprosartan—Rash—Erlotinib—kidney cancer	0.000209	0.000709	CcSEcCtD
Eprosartan—Dermatitis—Erlotinib—kidney cancer	0.000208	0.000708	CcSEcCtD
Eprosartan—Palpitations—Paclitaxel—kidney cancer	0.000208	0.000708	CcSEcCtD
Eprosartan—Hyponatraemia—Doxorubicin—kidney cancer	0.000208	0.000707	CcSEcCtD
Eprosartan—Insomnia—Gemcitabine—kidney cancer	0.000208	0.000707	CcSEcCtD
Eprosartan—Headache—Erlotinib—kidney cancer	0.000207	0.000705	CcSEcCtD
Eprosartan—Tinnitus—Capecitabine—kidney cancer	0.000207	0.000704	CcSEcCtD
Eprosartan—Loss of consciousness—Paclitaxel—kidney cancer	0.000207	0.000704	CcSEcCtD
Eprosartan—Constipation—Vincristine—kidney cancer	0.000207	0.000704	CcSEcCtD
Eprosartan—Pain—Vincristine—kidney cancer	0.000207	0.000704	CcSEcCtD
Eprosartan—Osteoarthritis—Doxorubicin—kidney cancer	0.000207	0.000704	CcSEcCtD
Eprosartan—Paraesthesia—Gemcitabine—kidney cancer	0.000206	0.000701	CcSEcCtD
Eprosartan—Cough—Paclitaxel—kidney cancer	0.000206	0.000699	CcSEcCtD
Eprosartan—Asthenia—Sunitinib—kidney cancer	0.000206	0.000699	CcSEcCtD
Eprosartan—Dyspnoea—Gemcitabine—kidney cancer	0.000205	0.000696	CcSEcCtD
Eprosartan—Nausea—Vinblastine—kidney cancer	0.000205	0.000695	CcSEcCtD
Eprosartan—Somnolence—Gemcitabine—kidney cancer	0.000204	0.000694	CcSEcCtD
Eprosartan—Migraine—Doxorubicin—kidney cancer	0.000204	0.000693	CcSEcCtD
Eprosartan—Nausea—Everolimus—kidney cancer	0.000204	0.000692	CcSEcCtD
Eprosartan—Diarrhoea—Sorafenib—kidney cancer	0.000204	0.000692	CcSEcCtD
Eprosartan—Pruritus—Sunitinib—kidney cancer	0.000203	0.000689	CcSEcCtD
Eprosartan—Chest pain—Paclitaxel—kidney cancer	0.000201	0.000682	CcSEcCtD
Eprosartan—Myalgia—Paclitaxel—kidney cancer	0.000201	0.000682	CcSEcCtD
Eprosartan—Arthralgia—Paclitaxel—kidney cancer	0.000201	0.000682	CcSEcCtD
Eprosartan—Anxiety—Paclitaxel—kidney cancer	0.0002	0.00068	CcSEcCtD
Eprosartan—Face oedema—Doxorubicin—kidney cancer	0.0002	0.00068	CcSEcCtD
Eprosartan—Decreased appetite—Gemcitabine—kidney cancer	0.0002	0.000679	CcSEcCtD
Eprosartan—Hypersensitivity—Dactinomycin—kidney cancer	0.0002	0.000679	CcSEcCtD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	0.0002	0.0165	CbGpPWpGaD
Eprosartan—Chills—Capecitabine—kidney cancer	0.000199	0.000678	CcSEcCtD
Eprosartan—Discomfort—Paclitaxel—kidney cancer	0.000198	0.000674	CcSEcCtD
Eprosartan—Fatigue—Gemcitabine—kidney cancer	0.000198	0.000674	CcSEcCtD
Eprosartan—Gastrointestinal pain—Vincristine—kidney cancer	0.000198	0.000673	CcSEcCtD
Eprosartan—Dizziness—Sorafenib—kidney cancer	0.000197	0.000669	CcSEcCtD
Eprosartan—Constipation—Gemcitabine—kidney cancer	0.000197	0.000668	CcSEcCtD
Eprosartan—Pain—Gemcitabine—kidney cancer	0.000197	0.000668	CcSEcCtD
Eprosartan—Nausea—Erlotinib—kidney cancer	0.000197	0.000668	CcSEcCtD
Eprosartan—Dry mouth—Paclitaxel—kidney cancer	0.000196	0.000667	CcSEcCtD
Eprosartan—Diarrhoea—Sunitinib—kidney cancer	0.000196	0.000666	CcSEcCtD
Eprosartan—Ataxia—Doxorubicin—kidney cancer	0.000195	0.000662	CcSEcCtD
Eprosartan—Asthenia—Dactinomycin—kidney cancer	0.000195	0.000661	CcSEcCtD
Eprosartan—Blood creatinine increased—Doxorubicin—kidney cancer	0.000194	0.000659	CcSEcCtD
Eprosartan—Abdominal pain—Vincristine—kidney cancer	0.000192	0.000651	CcSEcCtD
Eprosartan—Body temperature increased—Vincristine—kidney cancer	0.000192	0.000651	CcSEcCtD
Eprosartan—Flatulence—Capecitabine—kidney cancer	0.000191	0.000648	CcSEcCtD
Eprosartan—ABCC2—ABC-family proteins mediated transport—ABCB1—kidney cancer	0.000191	0.0158	CbGpPWpGaD
Eprosartan—Dizziness—Sunitinib—kidney cancer	0.000189	0.000644	CcSEcCtD
Eprosartan—Feeling abnormal—Gemcitabine—kidney cancer	0.000189	0.000644	CcSEcCtD
Eprosartan—Shock—Paclitaxel—kidney cancer	0.000189	0.000643	CcSEcCtD
Eprosartan—Vomiting—Sorafenib—kidney cancer	0.000189	0.000643	CcSEcCtD
Eprosartan—Orthostatic hypotension—Doxorubicin—kidney cancer	0.000189	0.000643	CcSEcCtD
Eprosartan—Hypokalaemia—Doxorubicin—kidney cancer	0.000189	0.000641	CcSEcCtD
Eprosartan—Thrombocytopenia—Paclitaxel—kidney cancer	0.000188	0.00064	CcSEcCtD
Eprosartan—Tachycardia—Paclitaxel—kidney cancer	0.000188	0.000638	CcSEcCtD
Eprosartan—Rash—Sorafenib—kidney cancer	0.000188	0.000638	CcSEcCtD
Eprosartan—Dermatitis—Sorafenib—kidney cancer	0.000188	0.000637	CcSEcCtD
Eprosartan—Back pain—Capecitabine—kidney cancer	0.000187	0.000636	CcSEcCtD
Eprosartan—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	0.000187	0.000634	CcSEcCtD
Eprosartan—Headache—Sorafenib—kidney cancer	0.000187	0.000634	CcSEcCtD
Eprosartan—Muscle spasms—Capecitabine—kidney cancer	0.000186	0.000632	CcSEcCtD
Eprosartan—Hyperhidrosis—Paclitaxel—kidney cancer	0.000186	0.000632	CcSEcCtD
Eprosartan—Diarrhoea—Dactinomycin—kidney cancer	0.000186	0.000631	CcSEcCtD
Eprosartan—Anorexia—Paclitaxel—kidney cancer	0.000183	0.000623	CcSEcCtD
Eprosartan—Gastritis—Doxorubicin—kidney cancer	0.000183	0.000623	CcSEcCtD
Eprosartan—Alanine aminotransferase increased—Doxorubicin—kidney cancer	0.000183	0.000621	CcSEcCtD
Eprosartan—Muscular weakness—Doxorubicin—kidney cancer	0.000183	0.000621	CcSEcCtD
Eprosartan—Vomiting—Sunitinib—kidney cancer	0.000182	0.000619	CcSEcCtD
Eprosartan—Body temperature increased—Gemcitabine—kidney cancer	0.000182	0.000618	CcSEcCtD
Eprosartan—Tremor—Capecitabine—kidney cancer	0.000181	0.000616	CcSEcCtD
Eprosartan—Rash—Sunitinib—kidney cancer	0.000181	0.000614	CcSEcCtD
Eprosartan—Dermatitis—Sunitinib—kidney cancer	0.00018	0.000613	CcSEcCtD
Eprosartan—Hypotension—Paclitaxel—kidney cancer	0.00018	0.000611	CcSEcCtD
Eprosartan—Ill-defined disorder—Capecitabine—kidney cancer	0.00018	0.00061	CcSEcCtD
Eprosartan—Headache—Sunitinib—kidney cancer	0.000179	0.00061	CcSEcCtD
Eprosartan—Asthma—Doxorubicin—kidney cancer	0.000179	0.000608	CcSEcCtD
Eprosartan—Hypersensitivity—Vincristine—kidney cancer	0.000179	0.000607	CcSEcCtD
Eprosartan—Nausea—Sorafenib—kidney cancer	0.000177	0.000601	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000175	0.000596	CcSEcCtD
Eprosartan—Malaise—Capecitabine—kidney cancer	0.000175	0.000593	CcSEcCtD
Eprosartan—Angina pectoris—Doxorubicin—kidney cancer	0.000174	0.000593	CcSEcCtD
Eprosartan—Insomnia—Paclitaxel—kidney cancer	0.000174	0.000592	CcSEcCtD
Eprosartan—Vertigo—Capecitabine—kidney cancer	0.000174	0.000591	CcSEcCtD
Eprosartan—Asthenia—Vincristine—kidney cancer	0.000174	0.000591	CcSEcCtD
Eprosartan—Syncope—Capecitabine—kidney cancer	0.000174	0.00059	CcSEcCtD
Eprosartan—Paraesthesia—Paclitaxel—kidney cancer	0.000173	0.000587	CcSEcCtD
Eprosartan—Vomiting—Dactinomycin—kidney cancer	0.000172	0.000586	CcSEcCtD
Eprosartan—Bronchitis—Doxorubicin—kidney cancer	0.000172	0.000585	CcSEcCtD
Eprosartan—Dyspnoea—Paclitaxel—kidney cancer	0.000172	0.000583	CcSEcCtD
Eprosartan—Somnolence—Paclitaxel—kidney cancer	0.000171	0.000581	CcSEcCtD
Eprosartan—Palpitations—Capecitabine—kidney cancer	0.000171	0.000581	CcSEcCtD
Eprosartan—Rash—Dactinomycin—kidney cancer	0.000171	0.000581	CcSEcCtD
Eprosartan—Nausea—Sunitinib—kidney cancer	0.00017	0.000578	CcSEcCtD
Eprosartan—Loss of consciousness—Capecitabine—kidney cancer	0.00017	0.000578	CcSEcCtD
Eprosartan—Dyspepsia—Paclitaxel—kidney cancer	0.000169	0.000576	CcSEcCtD
Eprosartan—Cough—Capecitabine—kidney cancer	0.000169	0.000574	CcSEcCtD
Eprosartan—Decreased appetite—Paclitaxel—kidney cancer	0.000167	0.000569	CcSEcCtD
Eprosartan—Upper respiratory tract infection—Doxorubicin—kidney cancer	0.000166	0.000565	CcSEcCtD
Eprosartan—Fatigue—Paclitaxel—kidney cancer	0.000166	0.000564	CcSEcCtD
Eprosartan—Diarrhoea—Vincristine—kidney cancer	0.000166	0.000563	CcSEcCtD
Eprosartan—Pollakiuria—Doxorubicin—kidney cancer	0.000165	0.000562	CcSEcCtD
Eprosartan—Asthenia—Gemcitabine—kidney cancer	0.000165	0.00056	CcSEcCtD
Eprosartan—Myalgia—Capecitabine—kidney cancer	0.000165	0.00056	CcSEcCtD
Eprosartan—Chest pain—Capecitabine—kidney cancer	0.000165	0.00056	CcSEcCtD
Eprosartan—Arthralgia—Capecitabine—kidney cancer	0.000165	0.00056	CcSEcCtD
Eprosartan—Constipation—Paclitaxel—kidney cancer	0.000165	0.000559	CcSEcCtD
Eprosartan—Pain—Paclitaxel—kidney cancer	0.000165	0.000559	CcSEcCtD
Eprosartan—Anxiety—Capecitabine—kidney cancer	0.000164	0.000558	CcSEcCtD
Eprosartan—AGTR1—Arf6 trafficking events—CDH1—kidney cancer	0.000164	0.0136	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—ABCB1—kidney cancer	0.000163	0.0135	CbGpPWpGaD
Eprosartan—Discomfort—Capecitabine—kidney cancer	0.000163	0.000553	CcSEcCtD
Eprosartan—Pruritus—Gemcitabine—kidney cancer	0.000163	0.000553	CcSEcCtD
Eprosartan—Hyperglycaemia—Doxorubicin—kidney cancer	0.000161	0.000549	CcSEcCtD
Eprosartan—Dry mouth—Capecitabine—kidney cancer	0.000161	0.000548	CcSEcCtD
Eprosartan—Nausea—Dactinomycin—kidney cancer	0.000161	0.000547	CcSEcCtD
Eprosartan—Dizziness—Vincristine—kidney cancer	0.00016	0.000545	CcSEcCtD
Eprosartan—Feeling abnormal—Paclitaxel—kidney cancer	0.000159	0.000539	CcSEcCtD
Eprosartan—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000157	0.000535	CcSEcCtD
Eprosartan—Diarrhoea—Gemcitabine—kidney cancer	0.000157	0.000535	CcSEcCtD
Eprosartan—Renal failure—Doxorubicin—kidney cancer	0.000157	0.000533	CcSEcCtD
Eprosartan—Neuropathy peripheral—Doxorubicin—kidney cancer	0.000156	0.000532	CcSEcCtD
Eprosartan—Shock—Capecitabine—kidney cancer	0.000155	0.000528	CcSEcCtD
Eprosartan—Urinary tract infection—Doxorubicin—kidney cancer	0.000155	0.000527	CcSEcCtD
Eprosartan—Conjunctivitis—Doxorubicin—kidney cancer	0.000155	0.000527	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—SLC5A3—kidney cancer	0.000155	0.0128	CbGpPWpGaD
Eprosartan—Thrombocytopenia—Capecitabine—kidney cancer	0.000155	0.000526	CcSEcCtD
Eprosartan—Tachycardia—Capecitabine—kidney cancer	0.000154	0.000524	CcSEcCtD
Eprosartan—Vomiting—Vincristine—kidney cancer	0.000154	0.000524	CcSEcCtD
Eprosartan—Urticaria—Paclitaxel—kidney cancer	0.000153	0.00052	CcSEcCtD
Eprosartan—Rash—Vincristine—kidney cancer	0.000153	0.000519	CcSEcCtD
Eprosartan—Hyperhidrosis—Capecitabine—kidney cancer	0.000153	0.000519	CcSEcCtD
Eprosartan—Dermatitis—Vincristine—kidney cancer	0.000153	0.000519	CcSEcCtD
Eprosartan—Haematuria—Doxorubicin—kidney cancer	0.000152	0.000517	CcSEcCtD
Eprosartan—Body temperature increased—Paclitaxel—kidney cancer	0.000152	0.000517	CcSEcCtD
Eprosartan—Abdominal pain—Paclitaxel—kidney cancer	0.000152	0.000517	CcSEcCtD
Eprosartan—Headache—Vincristine—kidney cancer	0.000152	0.000516	CcSEcCtD
Eprosartan—Epistaxis—Doxorubicin—kidney cancer	0.000151	0.000512	CcSEcCtD
Eprosartan—Anorexia—Capecitabine—kidney cancer	0.000151	0.000512	CcSEcCtD
Eprosartan—Sinusitis—Doxorubicin—kidney cancer	0.00015	0.000509	CcSEcCtD
Eprosartan—Hypotension—Capecitabine—kidney cancer	0.000148	0.000502	CcSEcCtD
Eprosartan—Vomiting—Gemcitabine—kidney cancer	0.000146	0.000497	CcSEcCtD
Eprosartan—Bradycardia—Doxorubicin—kidney cancer	0.000146	0.000496	CcSEcCtD
Eprosartan—Rash—Gemcitabine—kidney cancer	0.000145	0.000493	CcSEcCtD
Eprosartan—Dermatitis—Gemcitabine—kidney cancer	0.000145	0.000492	CcSEcCtD
Eprosartan—Headache—Gemcitabine—kidney cancer	0.000144	0.000489	CcSEcCtD
Eprosartan—Nausea—Vincristine—kidney cancer	0.000144	0.000489	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000144	0.000489	CcSEcCtD
Eprosartan—Rhinitis—Doxorubicin—kidney cancer	0.000144	0.000488	CcSEcCtD
Eprosartan—Insomnia—Capecitabine—kidney cancer	0.000143	0.000485	CcSEcCtD
Eprosartan—Pharyngitis—Doxorubicin—kidney cancer	0.000142	0.000483	CcSEcCtD
Eprosartan—Paraesthesia—Capecitabine—kidney cancer	0.000142	0.000482	CcSEcCtD
Eprosartan—Hypersensitivity—Paclitaxel—kidney cancer	0.000142	0.000482	CcSEcCtD
Eprosartan—Oedema peripheral—Doxorubicin—kidney cancer	0.000141	0.00048	CcSEcCtD
Eprosartan—Dyspnoea—Capecitabine—kidney cancer	0.000141	0.000479	CcSEcCtD
Eprosartan—Dyspepsia—Capecitabine—kidney cancer	0.000139	0.000472	CcSEcCtD
Eprosartan—Visual impairment—Doxorubicin—kidney cancer	0.000138	0.000469	CcSEcCtD
Eprosartan—Asthenia—Paclitaxel—kidney cancer	0.000138	0.000469	CcSEcCtD
Eprosartan—Decreased appetite—Capecitabine—kidney cancer	0.000137	0.000467	CcSEcCtD
Eprosartan—AGTR1—G alpha (q) signalling events—ITPR2—kidney cancer	0.000137	0.0113	CbGpPWpGaD
Eprosartan—Nausea—Gemcitabine—kidney cancer	0.000137	0.000464	CcSEcCtD
Eprosartan—Fatigue—Capecitabine—kidney cancer	0.000136	0.000463	CcSEcCtD
Eprosartan—Pruritus—Paclitaxel—kidney cancer	0.000136	0.000463	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—KEAP1—kidney cancer	0.000135	0.0112	CbGpPWpGaD
Eprosartan—Pain—Capecitabine—kidney cancer	0.000135	0.000459	CcSEcCtD
Eprosartan—Constipation—Capecitabine—kidney cancer	0.000135	0.000459	CcSEcCtD
Eprosartan—Tinnitus—Doxorubicin—kidney cancer	0.000134	0.000454	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—RELA—kidney cancer	0.000132	0.011	CbGpPWpGaD
Eprosartan—Diarrhoea—Paclitaxel—kidney cancer	0.000132	0.000448	CcSEcCtD
Eprosartan—Feeling abnormal—Capecitabine—kidney cancer	0.00013	0.000442	CcSEcCtD
Eprosartan—Gastrointestinal pain—Capecitabine—kidney cancer	0.000129	0.000439	CcSEcCtD
Eprosartan—Chills—Doxorubicin—kidney cancer	0.000129	0.000437	CcSEcCtD
Eprosartan—Dizziness—Paclitaxel—kidney cancer	0.000127	0.000433	CcSEcCtD
Eprosartan—Urticaria—Capecitabine—kidney cancer	0.000125	0.000426	CcSEcCtD
Eprosartan—Body temperature increased—Capecitabine—kidney cancer	0.000125	0.000424	CcSEcCtD
Eprosartan—Abdominal pain—Capecitabine—kidney cancer	0.000125	0.000424	CcSEcCtD
Eprosartan—CYP2C9—Xenobiotics—CYP1A1—kidney cancer	0.000123	0.0102	CbGpPWpGaD
Eprosartan—Flatulence—Doxorubicin—kidney cancer	0.000123	0.000418	CcSEcCtD
Eprosartan—Tension—Doxorubicin—kidney cancer	0.000122	0.000416	CcSEcCtD
Eprosartan—Vomiting—Paclitaxel—kidney cancer	0.000122	0.000416	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—ITPR2—kidney cancer	0.000122	0.0101	CbGpPWpGaD
Eprosartan—Rash—Paclitaxel—kidney cancer	0.000121	0.000412	CcSEcCtD
Eprosartan—Dermatitis—Paclitaxel—kidney cancer	0.000121	0.000412	CcSEcCtD
Eprosartan—Nervousness—Doxorubicin—kidney cancer	0.000121	0.000412	CcSEcCtD
Eprosartan—AGTR1—Arf6 trafficking events—CTNNB1—kidney cancer	0.000121	0.01	CbGpPWpGaD
Eprosartan—Back pain—Doxorubicin—kidney cancer	0.000121	0.00041	CcSEcCtD
Eprosartan—Headache—Paclitaxel—kidney cancer	0.000121	0.00041	CcSEcCtD
Eprosartan—Muscle spasms—Doxorubicin—kidney cancer	0.00012	0.000408	CcSEcCtD
Eprosartan—CYP2C9—Tamoxifen metabolism—CYP1A1—kidney cancer	0.000119	0.00982	CbGpPWpGaD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	0.000117	0.00969	CbGpPWpGaD
Eprosartan—Hypersensitivity—Capecitabine—kidney cancer	0.000116	0.000395	CcSEcCtD
Eprosartan—Ill-defined disorder—Doxorubicin—kidney cancer	0.000116	0.000393	CcSEcCtD
Eprosartan—AGTR1—G alpha (q) signalling events—ANXA1—kidney cancer	0.000114	0.00948	CbGpPWpGaD
Eprosartan—Nausea—Paclitaxel—kidney cancer	0.000114	0.000388	CcSEcCtD
Eprosartan—CYP2C9—Biological oxidations—ACY1—kidney cancer	0.000113	0.0094	CbGpPWpGaD
Eprosartan—Asthenia—Capecitabine—kidney cancer	0.000113	0.000385	CcSEcCtD
Eprosartan—AGTR1—Peptide ligand-binding receptors—ANXA1—kidney cancer	0.000113	0.00936	CbGpPWpGaD
Eprosartan—Malaise—Doxorubicin—kidney cancer	0.000112	0.000382	CcSEcCtD
Eprosartan—Vertigo—Doxorubicin—kidney cancer	0.000112	0.000381	CcSEcCtD
Eprosartan—Syncope—Doxorubicin—kidney cancer	0.000112	0.00038	CcSEcCtD
Eprosartan—Pruritus—Capecitabine—kidney cancer	0.000112	0.00038	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—OR4C13—kidney cancer	0.00011	0.00913	CbGpPWpGaD
Eprosartan—Palpitations—Doxorubicin—kidney cancer	0.00011	0.000375	CcSEcCtD
Eprosartan—Loss of consciousness—Doxorubicin—kidney cancer	0.00011	0.000373	CcSEcCtD
Eprosartan—Cough—Doxorubicin—kidney cancer	0.000109	0.00037	CcSEcCtD
Eprosartan—Diarrhoea—Capecitabine—kidney cancer	0.000108	0.000367	CcSEcCtD
Eprosartan—Arthralgia—Doxorubicin—kidney cancer	0.000106	0.000361	CcSEcCtD
Eprosartan—Myalgia—Doxorubicin—kidney cancer	0.000106	0.000361	CcSEcCtD
Eprosartan—Chest pain—Doxorubicin—kidney cancer	0.000106	0.000361	CcSEcCtD
Eprosartan—Anxiety—Doxorubicin—kidney cancer	0.000106	0.00036	CcSEcCtD
Eprosartan—Discomfort—Doxorubicin—kidney cancer	0.000105	0.000357	CcSEcCtD
Eprosartan—Dizziness—Capecitabine—kidney cancer	0.000104	0.000355	CcSEcCtD
Eprosartan—Dry mouth—Doxorubicin—kidney cancer	0.000104	0.000353	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—kidney cancer	0.000102	0.00848	CbGpPWpGaD
Eprosartan—Vomiting—Capecitabine—kidney cancer	0.0001	0.000341	CcSEcCtD
Eprosartan—Shock—Doxorubicin—kidney cancer	0.0001	0.00034	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—OR4C13—kidney cancer	0.0001	0.0083	CbGpPWpGaD
Eprosartan—Thrombocytopenia—Doxorubicin—kidney cancer	9.97e-05	0.000339	CcSEcCtD
Eprosartan—Rash—Capecitabine—kidney cancer	9.96e-05	0.000338	CcSEcCtD
Eprosartan—Dermatitis—Capecitabine—kidney cancer	9.95e-05	0.000338	CcSEcCtD
Eprosartan—Tachycardia—Doxorubicin—kidney cancer	9.94e-05	0.000338	CcSEcCtD
Eprosartan—Headache—Capecitabine—kidney cancer	9.89e-05	0.000336	CcSEcCtD
Eprosartan—Hyperhidrosis—Doxorubicin—kidney cancer	9.84e-05	0.000334	CcSEcCtD
Eprosartan—Anorexia—Doxorubicin—kidney cancer	9.7e-05	0.00033	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MAPK3—kidney cancer	9.58e-05	0.00793	CbGpPWpGaD
Eprosartan—Hypotension—Doxorubicin—kidney cancer	9.51e-05	0.000323	CcSEcCtD
Eprosartan—Nausea—Capecitabine—kidney cancer	9.38e-05	0.000319	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Doxorubicin—kidney cancer	9.28e-05	0.000315	CcSEcCtD
Eprosartan—Insomnia—Doxorubicin—kidney cancer	9.21e-05	0.000313	CcSEcCtD
Eprosartan—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	9.2e-05	0.00762	CbGpPWpGaD
Eprosartan—CYP2C9—Arachidonic acid metabolism—PTGS1—kidney cancer	9.2e-05	0.00762	CbGpPWpGaD
Eprosartan—Paraesthesia—Doxorubicin—kidney cancer	9.14e-05	0.000311	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MAPK1—kidney cancer	9.11e-05	0.00755	CbGpPWpGaD
Eprosartan—Dyspnoea—Doxorubicin—kidney cancer	9.08e-05	0.000308	CcSEcCtD
Eprosartan—Somnolence—Doxorubicin—kidney cancer	9.05e-05	0.000308	CcSEcCtD
Eprosartan—Dyspepsia—Doxorubicin—kidney cancer	8.96e-05	0.000305	CcSEcCtD
Eprosartan—Decreased appetite—Doxorubicin—kidney cancer	8.85e-05	0.000301	CcSEcCtD
Eprosartan—Fatigue—Doxorubicin—kidney cancer	8.78e-05	0.000298	CcSEcCtD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	8.77e-05	0.00726	CbGpPWpGaD
Eprosartan—Pain—Doxorubicin—kidney cancer	8.71e-05	0.000296	CcSEcCtD
Eprosartan—Constipation—Doxorubicin—kidney cancer	8.71e-05	0.000296	CcSEcCtD
Eprosartan—ABCC2—Transmembrane transport of small molecules—RYR1—kidney cancer	8.62e-05	0.00714	CbGpPWpGaD
Eprosartan—Feeling abnormal—Doxorubicin—kidney cancer	8.39e-05	0.000285	CcSEcCtD
Eprosartan—Gastrointestinal pain—Doxorubicin—kidney cancer	8.32e-05	0.000283	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—IL2—kidney cancer	8.26e-05	0.00684	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—SLC5A5—kidney cancer	8.16e-05	0.00676	CbGpPWpGaD
Eprosartan—Urticaria—Doxorubicin—kidney cancer	8.09e-05	0.000275	CcSEcCtD
Eprosartan—Body temperature increased—Doxorubicin—kidney cancer	8.05e-05	0.000274	CcSEcCtD
Eprosartan—Abdominal pain—Doxorubicin—kidney cancer	8.05e-05	0.000274	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—kidney cancer	7.91e-05	0.00655	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—SLC2A1—kidney cancer	7.88e-05	0.00653	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ANXA1—kidney cancer	7.58e-05	0.00628	CbGpPWpGaD
Eprosartan—Hypersensitivity—Doxorubicin—kidney cancer	7.5e-05	0.000255	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—EGR1—kidney cancer	7.32e-05	0.00606	CbGpPWpGaD
Eprosartan—Asthenia—Doxorubicin—kidney cancer	7.3e-05	0.000248	CcSEcCtD
Eprosartan—Pruritus—Doxorubicin—kidney cancer	7.2e-05	0.000245	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—VEGFA—kidney cancer	7.02e-05	0.00582	CbGpPWpGaD
Eprosartan—Diarrhoea—Doxorubicin—kidney cancer	6.97e-05	0.000237	CcSEcCtD
Eprosartan—Dizziness—Doxorubicin—kidney cancer	6.73e-05	0.000229	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—GSTP1—kidney cancer	6.57e-05	0.00544	CbGpPWpGaD
Eprosartan—Vomiting—Doxorubicin—kidney cancer	6.47e-05	0.00022	CcSEcCtD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	6.44e-05	0.00534	CbGpPWpGaD
Eprosartan—Rash—Doxorubicin—kidney cancer	6.42e-05	0.000218	CcSEcCtD
Eprosartan—Dermatitis—Doxorubicin—kidney cancer	6.41e-05	0.000218	CcSEcCtD
Eprosartan—Headache—Doxorubicin—kidney cancer	6.38e-05	0.000217	CcSEcCtD
Eprosartan—CYP2C9—Biological oxidations—ALDH1A1—kidney cancer	6.21e-05	0.00515	CbGpPWpGaD
Eprosartan—Nausea—Doxorubicin—kidney cancer	6.05e-05	0.000206	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—GSTM1—kidney cancer	6.04e-05	0.005	CbGpPWpGaD
Eprosartan—CYP2C9—Arachidonic acid metabolism—CYP1A1—kidney cancer	5.93e-05	0.00491	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—OR4C13—kidney cancer	5.92e-05	0.0049	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—ANXA1—kidney cancer	5.77e-05	0.00478	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—POMC—kidney cancer	5.54e-05	0.00459	CbGpPWpGaD
Eprosartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	5.12e-05	0.00424	CbGpPWpGaD
Eprosartan—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	5.05e-05	0.00419	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—LATS1—kidney cancer	5.03e-05	0.00417	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—SLC5A3—kidney cancer	4.95e-05	0.0041	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ANXA2—kidney cancer	4.95e-05	0.0041	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ATP7B—kidney cancer	4.95e-05	0.0041	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—AKAP13—kidney cancer	4.58e-05	0.00379	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—AMER1—kidney cancer	4.28e-05	0.00354	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—AKAP13—kidney cancer	4.16e-05	0.00344	CbGpPWpGaD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	4.15e-05	0.00344	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—kidney cancer	4.14e-05	0.00343	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—ITPR2—kidney cancer	3.89e-05	0.00323	CbGpPWpGaD
Eprosartan—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	3.82e-05	0.00316	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	3.71e-05	0.00308	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GSTT1—kidney cancer	3.65e-05	0.00303	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—GPC3—kidney cancer	3.58e-05	0.00297	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CER1—kidney cancer	3.58e-05	0.00297	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—ITPR2—kidney cancer	3.54e-05	0.00293	CbGpPWpGaD
Eprosartan—CYP2C9—Arachidonic acid metabolism—PTGS2—kidney cancer	3.52e-05	0.00292	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—PTGS1—kidney cancer	3.42e-05	0.00283	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—ANXA1—kidney cancer	3.26e-05	0.0027	CbGpPWpGaD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—POMC—kidney cancer	3.1e-05	0.00256	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SFRP2—kidney cancer	3.05e-05	0.00252	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	3.02e-05	0.0025	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—kidney cancer	2.98e-05	0.00247	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—ANXA1—kidney cancer	2.96e-05	0.00245	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—kidney cancer	2.84e-05	0.00235	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—POMC—kidney cancer	2.83e-05	0.00234	CbGpPWpGaD
Eprosartan—AGTR1—G alpha (q) signalling events—PIK3CA—kidney cancer	2.75e-05	0.00228	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—kidney cancer	2.68e-05	0.00222	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—SLC5A5—kidney cancer	2.61e-05	0.00216	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GSTP1—kidney cancer	2.53e-05	0.0021	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—SLC2A1—kidney cancer	2.52e-05	0.00209	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—GSTP1—kidney cancer	2.5e-05	0.00207	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—kidney cancer	2.46e-05	0.00204	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CASP2—kidney cancer	2.46e-05	0.00203	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—AKAP13—kidney cancer	2.46e-05	0.00203	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GSTM1—kidney cancer	2.33e-05	0.00193	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—GSTM1—kidney cancer	2.29e-05	0.0019	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—GRB7—kidney cancer	2.25e-05	0.00186	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—CYP1A1—kidney cancer	2.21e-05	0.00183	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—CYP1A1—kidney cancer	2.17e-05	0.0018	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ITPR2—kidney cancer	2.09e-05	0.00173	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ABCB1—kidney cancer	1.99e-05	0.00165	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ACY1—kidney cancer	1.94e-05	0.00161	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CTNNA1—kidney cancer	1.89e-05	0.00157	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HSPB1—kidney cancer	1.88e-05	0.00156	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EIF4EBP1—kidney cancer	1.88e-05	0.00156	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PSMD7—kidney cancer	1.75e-05	0.00145	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TSC1—kidney cancer	1.75e-05	0.00145	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ANXA1—kidney cancer	1.75e-05	0.00145	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FLT1—kidney cancer	1.7e-05	0.0014	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	1.65e-05	0.00137	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PDHB—kidney cancer	1.65e-05	0.00137	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—POMC—kidney cancer	1.64e-05	0.00136	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—POMC—kidney cancer	1.6e-05	0.00132	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—JUNB—kidney cancer	1.57e-05	0.0013	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PAK1—kidney cancer	1.57e-05	0.0013	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CCBL1—kidney cancer	1.55e-05	0.00128	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—POMC—kidney cancer	1.45e-05	0.0012	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	1.4e-05	0.00116	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PPAT—kidney cancer	1.34e-05	0.00111	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GLIPR1—kidney cancer	1.34e-05	0.00111	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	1.33e-05	0.0011	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	1.31e-05	0.00109	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IGF2—kidney cancer	1.28e-05	0.00106	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CDKN2B—kidney cancer	1.28e-05	0.00106	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—FH—kidney cancer	1.25e-05	0.00104	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—APRT—kidney cancer	1.25e-05	0.00104	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IGF1R—kidney cancer	1.24e-05	0.00103	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	1.22e-05	0.00101	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—RAF1—kidney cancer	1.2e-05	0.000991	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—IL2—kidney cancer	1.18e-05	0.000979	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GPC3—kidney cancer	1.18e-05	0.000973	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CA2—kidney cancer	1.14e-05	0.000947	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—RAF1—kidney cancer	1.13e-05	0.000933	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ALAD—kidney cancer	1.11e-05	0.000923	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ST3GAL2—kidney cancer	1.09e-05	0.000901	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL2—kidney cancer	1.07e-05	0.000889	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ALDH1A1—kidney cancer	1.06e-05	0.00088	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HIF1A—kidney cancer	1.02e-05	0.000847	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TSC2—kidney cancer	1.02e-05	0.000845	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PGK1—kidney cancer	1.02e-05	0.000844	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SLC5A3—kidney cancer	1.02e-05	0.000844	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—LDHB—kidney cancer	9.99e-06	0.000828	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KDR—kidney cancer	9.78e-06	0.00081	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—APC—kidney cancer	9.01e-06	0.000746	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KIT—kidney cancer	9.01e-06	0.000746	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CA9—kidney cancer	8.66e-06	0.000718	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—MAPK3—kidney cancer	8.63e-06	0.000715	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—POMC—kidney cancer	8.58e-06	0.00071	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	8.47e-06	0.000701	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—BRAF—kidney cancer	8.47e-06	0.000701	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—MAPK1—kidney cancer	8.21e-06	0.00068	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CA—kidney cancer	7.84e-06	0.00065	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—KRAS—kidney cancer	7.75e-06	0.000642	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CRABP1—kidney cancer	7.37e-06	0.00061	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CA—kidney cancer	7.12e-06	0.00059	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—RAF1—kidney cancer	7.07e-06	0.000586	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—RELA—kidney cancer	7.04e-06	0.000583	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ERBB2—kidney cancer	7e-06	0.000579	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MTOR—kidney cancer	6.9e-06	0.000572	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ITPR2—kidney cancer	6.85e-06	0.000567	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CDKN1B—kidney cancer	6.48e-06	0.000537	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL2—kidney cancer	6.34e-06	0.000525	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	6.31e-06	0.000523	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTT1—kidney cancer	6.25e-06	0.000517	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ACHE—kidney cancer	6.25e-06	0.000517	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCND1—kidney cancer	6.18e-06	0.000512	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—JUN—kidney cancer	6.17e-06	0.000511	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CTNNB1—kidney cancer	6.12e-06	0.000507	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PTEN—kidney cancer	5.97e-06	0.000494	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SCARB1—kidney cancer	5.91e-06	0.00049	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PTGS1—kidney cancer	5.85e-06	0.000485	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PSMD7—kidney cancer	5.74e-06	0.000475	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—BCHE—kidney cancer	5.44e-06	0.000451	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—VEGFA—kidney cancer	5.39e-06	0.000446	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SLC5A5—kidney cancer	5.37e-06	0.000445	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SLC2A1—kidney cancer	5.19e-06	0.00043	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MAPK3—kidney cancer	5.1e-06	0.000422	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	5.04e-06	0.000417	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MYC—kidney cancer	4.96e-06	0.000411	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MAPK1—kidney cancer	4.85e-06	0.000402	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KRAS—kidney cancer	4.58e-06	0.000379	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.39e-06	0.000364	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTP1—kidney cancer	4.33e-06	0.000359	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CA—kidney cancer	4.21e-06	0.000349	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ABCB1—kidney cancer	4.1e-06	0.000339	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TP53—kidney cancer	4.07e-06	0.000337	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTM1—kidney cancer	3.98e-06	0.00033	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP1A1—kidney cancer	3.77e-06	0.000312	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.1e-06	0.000257	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—POMC—kidney cancer	2.81e-06	0.000233	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PTGS2—kidney cancer	2.24e-06	0.000186	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PTEN—kidney cancer	1.96e-06	0.000162	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CA—kidney cancer	1.38e-06	0.000114	CbGpPWpGaD
